Bayer has told U.S. lawmakers it could stop selling Roundup weedkiller unless they can strengthen legal protection against product liability litigation.

Bayer tells US it could halt Roundup weedkiller sales over legal risks

Bayer’s shares sink to 20-year low on 2025 earnings fall forecast
Bayer said on Tuesday that weak agricultural markets mean its earnings are likely to fall further next year, sparking a sharp fall in the German company's shares and piling pressure on its CEO to deliver on his turnaround efforts.

Bayer investor Deka takes a stand against CEO in annual vote
Bayer shareholder Deka Investment said on Friday it would not join other large investors in supporting the healthcare and agriculture group's management at its annual general meeting.

Bayer confirms 2024 outlook despite slow start for agriculture, consumer health units
Bayer confirmed its full-year forecast for earnings and cash flow on Monday despite slow business at its crop science and consumer health divisions.

Bayer under investor pressure to speed up CEO changeover
Drug and chem firm's stock in 'crisis of trust,' investor says
Frankfurt | Reuters — A top-10 shareholder in Bayer on Tuesday called on the group’s supervisory board to replace CEO Werner Baumann quickly, adding to investor pressure to restore trust and revive the German drugmaker’s sagging share price. Despite recent improvements in the company’s agriculture business and drug development prospects, Bayer shares have been weighed […] Read more

Bayer’s agriculture unit, consumer health drive outlook hike
Frankfurt | Reuters – Agriculture and pharmaceuticals company Bayer BAYGn.DE on Thursday lifted its 2022 earnings guidance on strong demand from farmers for its seeds and crop chemicals and higher sales of consumer health products. Bayer is now targeting earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, of about 13 billion […] Read more

Bayer takes major writedown, flags Roundup settlement bill
Company writes down agribusiness assets
Frankfurt | Reuters — Bayer is facing a double hit from a higher legal bill for claims relating to weedkiller Roundup as well as 9.25 billion euros (C$14.2 billion) in impairments on agriculture businesses, much of it related to its Monsanto deal. The company said the write-downs, driven by weaker demand from farmers due to […] Read more

Bayer books second-quarter loss after settlement
Frankfurt | Reuters — German drugs and pesticides group Bayer reported a 9.5 billion-euro (C$14.86 billion) net loss for its second quarter, following a US$10.9 billion settlement of U.S. lawsuits claiming that its Roundup herbicide caused cancer. The charges stemmed mainly from agreements which attempted to wrap up legal disputes inherited with its US$63 billion […] Read more

Bayer puts Roundup future claims settlement on hold
Judge questions proposal for third-party scientists to rule on chemical's carcinogenicity
Frankfurt | Reuters — Bayer was forced on Wednesday to delay part of a proposed settlement of allegations that its widely used herbicide Roundup caused cancer after a U.S. judge questioned its plan to deal with future claims. The German company said that lawyers representing those preparing a class action had withdrawn a request for […] Read more

Bayer reportedly near glyphosate settlement after lengthy talks
Proposed settlement said to include $2 billion for future cases
Reuters — Germany’s Bayer is set to reach a settlement this week with U.S. plaintiffs that claim its glyphosate-based herbicides cause cancer, two people familiar with the matter told Reuters. After more than a year of talks, however, some details and the overall amount of the settlement have yet to be finalised, one of the […] Read more